← Leaderboards
William C Zamboni
Univ Of North Carolina Chapel Hill
$5,390,027
Attributed
$9,599,434
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,599,434 · 7
By mechanism
R01$7,113,776 · 3
P30$1,708,252 · 2
R21$390,742 · 1
U54$386,664 · 1
Top collaborators
- Sha X Chang5 shared
- Alexander V Kabanov5 shared
- Steven K. Libutti5 shared
- Samuel Lai4 shared
- Victoria Lin Bae-Jump2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Joseph G Ibrahim$17,599,307
- Sha X Chang$2,472,824
- Samuel Lai$12,082,303
- Weili Lin$21,939,114
- Victoria Lin Bae-Jump$4,533,215
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDrug KineticsTumorNanoparticleAntineoplastic AgentsDrug DevelopmentToxic EffectSmall MoleculePlasmaClinical ResearchGrantGenetically Engineered MouseLiposomesCancer CenterMalignant Breast NeoplasmPharmacodynamicsPre-Clinical ModelProgramsMediatingOncologySamplingCollaborationsMolecularFunding
Grant awards (35)
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors$555,851
R01 · FY2025 · CA · contact PI
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors$528,058
R01 · FY2024 · CA · contact PI
Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer$172,653
R21 · FY2024 · CA
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors$544,735
R01 · FY2023 · CA · contact PI
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors$544,735
R01 · FY2022 · CA · contact PI
Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer$218,089
R21 · FY2022 · CA
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$674,568
R01 · FY2021 · HL
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer Tumors$569,509
R01 · FY2021 · CA · contact PI
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$685,484
R01 · FY2020 · HL
Analytical Chemistry & Pharmacology$107,367
P30 · FY2020 · CA · contact PI
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$664,881
R01 · FY2019 · HL
Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy$334,212
R01 · FY2019 · CA
Analytical Chemistry & Pharmacology$104,071
P30 · FY2019 · CA · contact PI
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$633,547
R01 · FY2018 · HL
Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy$344,549
R01 · FY2018 · CA
Analytical Chemistry & Pharmacology$107,370
P30 · FY2018 · CA · contact PI
Analytical Chemistry & Pharmacology$2,968
P30 · FY2018 · CA · contact PI
Analytical Chemistry & Pharmacology$2,103
P30 · FY2018 · CA · contact PI
Analytical Chemistry & Pharmacology$1,367
P30 · FY2018 · CA · contact PI
Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy$344,549
R01 · FY2017 · CA
Analytical Chemistry & Pharmacology$105,332
P30 · FY2017 · CA · contact PI
Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy$344,549
R01 · FY2016 · CA
Analytical Chemistry & Pharmacology$105,959
P30 · FY2016 · CA · contact PI
Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy$344,549
R01 · FY2015 · CA
Analytical Chemistry and Pharmacology Core Facility$232,443
P30 · FY2015 · CA · contact PI
Analytical Chemistry and Pharmacology Core Facility$225,770
P30 · FY2014 · CA · contact PI
Analytical and Pharmacokinetics Core$75,985
U54 · FY2014 · CA · contact PI
Analytical Chemistry and Pharmacology Core Facility$228,994
P30 · FY2013 · CA · contact PI
Analytical and Pharmacokinetics Core$73,247
U54 · FY2013 · CA · contact PI
Analytical Chemistry and Pharmacology Core Facility$239,629
P30 · FY2012 · CA · contact PI
Analytical and Pharmacokinetics Core$78,337
U54 · FY2012 · CA · contact PI
Analytical Chemistry and Pharmacology Core Facility$2,552
P30 · FY2012 · CA · contact PI
Analytical Chemistry and Pharmacology Core Facility$242,327
P30 · FY2011 · CA · contact PI
Analytical and Pharmacokinetics Core$78,337
U54 · FY2011 · CA · contact PI
Analytical and Pharmacokinetics Core$80,758
U54 · FY2010 · CA · contact PI